亚洲社会药学

本期目录

2016年, 第11卷, 第4期　刊出日期：2016-12-20 上一期    下一期

论文

Select

Analysis of 431 Cases of Serious Adverse Drug Reaction/Event Caused by Shenmai Injection Xu Rongqin, Fu Wen, Yang Yue 2016 (4):  129-134.  摘要 ( 328 )   PDF(372KB) ( 366 )   Objective To analyze the serious cases of adverse drug reaction/adverse drug event (ADR/ADE) caused by Shenmai injection (SMI) produced by enterprises in Yunnan in 5 years and to provide references for reducing the risks of clinical drug use. Methods A total of 431 cases of serious ADR/ADE caused by SMI by Yunnan enterprises reported in adverse drug reaction monitoring system in China between January 2009 and December 2013 were analyzed. Results and Conclusion The serious ADR/ADE caused by SMI was related to the clinical irrational use, product features and inadequate instructions. Therefore, it is suggested that medical staff should regulate drug use process in accordance with the instructions; enterprises should actively carry out post-marketing safety studies to reduce the risk of drug use. 相关文章 | 计量指标

Select

Analysis of 4,562 Cases of Adverse Drug Reaction/Event Caused by Cefoperazone Sodium and Sulbactam Sodium for Injection Wei Fenfang, Zhang Zhongyi, Zheng Yongxia, Yang Yue 2016 (4):  135-143.  摘要 ( 497 )   PDF(584KB) ( 743 )   Objective To make a brief introduction of the marketing status of cefoperazone sodium and sulbactam sodium for injection at home and abroad and to find out risks of clinical drug use through analyzing two product instructions from Chinese and American medical enterprises and the adverse reaction reports from a provincial spontaneous reporting system (SRS). Methods Retrospective and descriptive methods were used to analyze 4,562 cases of adverse drug reaction/event (ADR/ADE) of cefoperazone sodium and sulbactam sodium for injection collected from January 1, 2004 to December 31, 2013. Results and Conclusion Adverse Drug Reaction Information Bulletin had a significant impact on the number of ADR reports in the SRS; 0–9 years old children were more prone to ADR; allergic shock was detected as the most severe ADR signal; irrational drug use was prominent; drug instructions from domestic producers was not specific enough. The use of ceftriaxone sodium for injection should be improved and the incidence of ADR/ADE should be reduced. 相关文章 | 计量指标

Select

Social Responsibility of the Pharmaceutical Manufacturers in China: Current Status and Countermeasures Li Chunyu, Zhao Yinghuan 2016 (4):  144-149.  摘要 ( 377 )   PDF(393KB) ( 380 )   Objective To improve social responsibility consciousness of pharmaceutical manufacturers and to provide suggestions for them to fulfill social responsibility. Methods Five aspects, including raw materials procurement, production, market supplement, sales and management were explored to analyze the current status and the problems in social responsibility of pharmaceutical manufacturers, and suggestions were put forward. Results and Conclusion At present, there are still defects in the every step of the operation of pharmaceutical manufacturers, which shows the lack of social responsibility consciousness. The enterprises procure poor quality raw materials for reducing the cost and the suppliers are scattered everywhere; pollution and safety problems still exist in the process of producing; enterprises use illegal means to disrupt the market and the supplement structure is not reasonable; enterprises use false advertisements to mislead consumers in selling and the sales personnel do not have high quality; decisionmakers have their limitations etc. Through self-examination, self-inspection and self-correction, the enterprises should ensure the source of raw materials, reduce the pollution and increase investment in scientific research. They should also guarantee quality and safety in production, reduce unnecessary additional cost and use the corporate culture to influence employees to perform the social responsibility actively, so that pharmaceutical enterprises in China develop sustainably and harmoniously. 相关文章 | 计量指标

Select

Pros and Cons Analysis of New Media and Traditional Media for OTC Advertisement Shao Xuefei, Wang Shuling 2016 (4):  150-154.  摘要 ( 532 )   PDF(451KB) ( 630 )   Objective To provide references for OTC enterprises to select appropriate advertisement media by analyzing the characteristic differences between new media and traditional media. Methods Literature review, expert interviews and comparative methods were used to study the advertisement features and profit points that new media and traditional media will bring to OTC enterprises respectively. Results and Conclusion OTC advertisement features of traditional media and new media were, firstly, compared. Secondly, quantitative analysis from 7 aspects such as economy, timeliness, coverage, target, interaction, audience recognition and the richness of content were analyzed from 10 kinds of media forms. Lastly, the effect of advertisements and the profit points of OTC enterprises were investigated. Different media advertisement can bring different profit points for OTC enterprises. Therefore, when choosing advertisements, OTC enterprises should select the appropriate media based on OTC advertisement target to distribute the costs. In addition, traditional media and new media should be integrated to bring the enterprise benefits. 相关文章 | 计量指标

Select

Research on Acquiring Data for Pharmacoeconomic Evaluation Duan Xiaomin, Lu Yan, Sun Lihua 2016 (4):  155-157.  摘要 ( 401 )   PDF(339KB) ( 294 )   Objective To improve the methods for acquiring data for pharmacoeconomic evaluation at a low-cost in Liaoning Shenyang. Methods Literature review and field survey were used to analyze the problems in the current data accumulation in Shenyang. Results and Conclusion The sources of data mainly come from medical records, health files and medical insurance database as the retrospective methods. Three databases collect enough data for pharmacoeconomic evaluation, but there are still some problems. Suggestions are raised to strengthen the management of the medical records in hospitals and community to ensure that the records are complete, standardized and authentic. The management of adverse drug reaction records should be strengthened. Medical insurance data should be improved and standardized by learning the successful experience of other countries and regions. 相关文章 | 计量指标

Select

Medical Insurance Data in China from Pharmacoeconomic Evaluation Perspective: Problems and Countermeasures Lu Yan, Ren Xiaoxiao, Jia Yaozhu, Sun Lihua 2016 (4):  158-162.  摘要 ( 358 )   PDF(360KB) ( 317 )   Objective To standardize the data accumulated in medical insurance database in China, make it meet pharmacoeconomic evaluation requirement so as to reduce the cost of data acquisition and improve the efficiency. Methods Literature review and field survey were used to analyze the current status and problems in medical insurance data collection in China from the requirement of pharmacoeconomic evaluation. Results and Conclusion In terms of completeness, the database lacked valid data and related information of adverse drug reactions. In terms of usability, there were problems such as chaos of disease diagnosis records and some drugs without trade names. As to data acquisition, the public did not have any permission to access the data. The data structure should be improved and the database should be standardized. At the same time, some measures should be taken to solve the problems in data transmission, to strengthen data monitoring, increase data usability, set up data application procedures and improve the efficiency of data obtaining. 相关文章 | 计量指标

Select

Dynamic Evaluation on Scientific and Technological Innovation Efficiency of Medical Universities in China Tan Xiaodong, Chen Yuwen 2016 (4):  163-168.  摘要 ( 389 )   PDF(550KB) ( 1164 )   Objective To promote scientific and technological innovation management and optimize technology resources by evaluating scientific and technological innovation efficiency of medical universities in China dynamically. Methods Combined with factor analysis theory, Malmquist index model was made to evaluate technological progress with variable scale, pure technical efficiency and scale efficiency of medical universities in 30 provinces (autonomous regions and municipalities under the central government) from 2008 to 2012. Results and Conclusion Medical scientific and technological innovation efficiency in China dropped by an annual rate of 1.2% from 2008 to 2012. Scientific and technological innovation efficiency of medical universities in China was affected by the decline of technological progress, which continued its downward trend. 相关文章 | 计量指标